Navigation Links
Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance
Date:6/4/2008

rence call June 5, 2008 at 8:30 a.m. (EDT) to review this outlook. Investors are invited to participate in this conference call with Dr. Gioacchino De Chirico, President and Chief Executive Officer; Rick Flynt, Chief Financial Officer; and Edward L. Gallup, consultant. The call will focus on the outlook for fiscal 2009 and general business trends. This press release will be posted on Immucor's website, as well as any material financial information that may be discussed by Messrs. De Chirico, Flynt or Gallup during this call that is not contained in the release. To access this information once posted, go to Immucor's website at http://www.immucor.com and click on "About Us - Press Releases."

To participate in the telephone conference call, dial 1-888-829-8668, pass code BLUD. Replays of the conference call will be available for one week beginning at 12:00 PM on June 5, 2008 by calling 1-866-508-6479. Beginning June 12, 2008, audio of the conference call or a transcript of the audio will be available on the "About Us - Press Releases" page of the Immucor website.

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments.

For more information on Immucor, please visit our website at http://www.immucor.com .

Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by word
'/>"/>

SOURCE Immucor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immucor CEOs Italian Trial Moves Toward Second Phase
2. Immucor To Acquire BioArray Solutions Ltd.
3. Immucor Responding to FTC Inquiry
4. Immucor Settles SEC Investigation
5. Martek Announces Second Quarter 2008 Financial Results
6. WWMR, Inc. Announces Launch of New Pain Clinic Monitor
7. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
8. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
9. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
10. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
11. Cynosure Announces Schedule of Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... (Nasdaq:,SIAL) announced today the global release of ... researchers to reproducibly,interrogate gene function, via siRNA ... not been considered amenable to conventional lipid-based,siRNA ... reagents exhibit a number,of drawbacks, including high ...
... DIEGO, Oct. 18 Volcano Corporation,(Nasdaq: VOLC ) ... shares of its common stock at a price of ... by Volcano. Volcano has granted the,underwriters a 30-day option ... common stock to cover over-allotments, if any. The offering,is ...
... Oct. 17 AMICAS, Inc. (Nasdaq: AMCS ),a ... today announced it will present to and meet with ... being held in New,York. (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... -- Presentation begins promptly at 10:20 a.m. (Eastern ...
Cached Biology Technology:Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types 2Volcano Corporation Announces Pricing of Common Stock Offering 2
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... CitiusTech announced today that its BI-Clinical platform ... ACO quality measures that are part of the ACO ... BI-Clinical can now help ACO participants assess ... four domains - patient / caregiver experience, care coordination ...
... FLAGSTAFF, Ariz. More peer-reviewed scientific studies of ... and operations are needed to adequately assess their impact, ... literature review conducted by the U.S. Geological Survey and ... their literature review, the authors of the paper, USGS ...
... New findings by Virginie Stevens ( CNRS ), ... Naturelle ) and colleagues show that interactions between dispersal ... study was published as open access paper in the ... dispersal plays a key role in gene flow among ...
Cached Biology News:BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS 2Literature review on solar energy and wildlife impacts research 2Butterflies: 'Twice-punished' by habitat fragmentation and climate change 2
mIGSF4A Aff Pur PAb...
Human IL-19 MAb (Clone 152112)...
SRY (sex determining region Y)-box 10...
... Steel Staining tray 19 x 29 cm, ... and blot processing.Automated staining of Coomassie Blue ... acid analysis. Prepares blots for high sensitivity ... of protocol, solution, volume, and processing time.Proven ...
Biology Products: